首页 工具
登录
购物车
(±)-Ibipinabant

(±)-Ibipinabant

产品编号 T4654   CAS 362519-49-1
别名: (±)-BMS6462, SLV319, (±)-SLV319

(±)-Ibipinabant ((±)-SLV319) 是一种有效选择性的大麻素-1 (CB-1) 受体拮抗剂,IC50=22 nM。(±)-SLV319 是 SLV319的消旋体。

TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
(±)-Ibipinabant Chemical Structure
(±)-Ibipinabant, CAS 362519-49-1
规格 价格/CNY 货期 数量
1 mg ¥ 343 现货
2 mg ¥ 497 现货
5 mg ¥ 779 现货
10 mg ¥ 1,360 现货
25 mg ¥ 2,910 现货
50 mg ¥ 4,290 现货
100 mg ¥ 6,130 现货
500 mg ¥ 12,500 现货
1 mL * 10 mM (in DMSO) ¥ 885 现货
其他形式的 (±)-Ibipinabant:
618惊喜特惠 4重福利大放送
药物设计专题培训
千万补贴 助力科研
产品目录号及名称: (±)-Ibipinabant (T4654)
点击图片重新获取验证码
选择批次  
纯度: 99.83%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 (±)-Ibipinabant ((±)-SLV319) has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.
靶点活性 CB1 :22nM
体外活性 Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Ibipinabant is a new, potent [Ki (CB1)=7.8 nM] and selective [Ki (CB2)=7.943 nM] CB1 antagonist [pA2 for arachidonic acid release in CHO cells=9.9] with in vitro pharmacological characteristics similar to rimonabant including inverse agonism and brain penetrance[3].
体内活性 Ibipinabant (3 mg/kg) reduces unfasted glucose to a significantly greater degree than rimonabant at the same dose on days 17, 28 and 38. Chronic treatment with ibipinabant significantly attenuates the progression of diabetes in ZDF rats, blunting the increase in blood glucose and HbA1c over time. Ibipinabant also reduces the hyperinsulinemia apparent at 6-8 weeks of age and attenuates the dramatic reduction in insulin levels observed 1-2 weeks later[3].
动物实验 Rats: SLV319, rimonabant and rosiglitazone are suspended in a 10% dimethylacetamide, 10% cremophor, 10% ethanol and 70% water vehicle. Drugs are administered by oral gavage in a volume of 2 mL/kg body weight at 09:00 hours every day. Treatment groups are as follows: (i) Vehicle: ad libitum access to food (vehicle), (ii) Vehicle: restricted access to food (20% less than average food intake of ad libitum vehicle-treated group for the first 3 days of the study, then 10% less than the average food intake of the ad libitum vehicle-treated group for the remainder of the study) (restricted), (iii) Rosiglitazone (4 mg/kg), (iv) Rimonabant (3 mg/kg) (RIM 3 mg/kg), (v) Rimonabant (10 mg/kg) (RIM 10 mg/kg), (vi) SLV319 (3 mg/kg) (IBI 3 mg/kg) and (vii) Ibipinabant (10 mg/kg) (IBI 10 mg/kg). Rosiglitazone is used as a positive control for its ability to delay β-cell decline, and rimonabant is used as a positive control for CB1 antagonism[3].
别名 (±)-BMS6462, SLV319, (±)-SLV319
分子量 487.4
分子式 C23H20Cl2N4O2S
CAS No. 362519-49-1

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 45 mg/mL (92.33 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0517 mL 10.2585 mL 20.517 mL 51.2926 mL
5 mM 0.4103 mL 2.0517 mL 4.1034 mL 10.2585 mL
10 mM 0.2052 mL 1.0259 mL 2.0517 mL 5.1293 mL
20 mM 0.1026 mL 0.5129 mL 1.0259 mL 2.5646 mL
50 mM 0.041 mL 0.2052 mL 0.4103 mL 1.0259 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Chorvat RJ, et al. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80. 2. Lange JH, et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem. 2004 Jan 29;47(3):627-43. 3. Rohrbach K, et al. Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes Metab. 2012 Jun;14(6):555-64.
β-Caryophyllene CB1 antagonist 1 CB1 agonist 1 AZD1940 Hemopressin (human, mouse) acetate Rimonabant PSNCBAM-1 Tedalinab

相关化合物库

该产品包含在如下化合物库中:
抗癌临床化合物库 GPCR靶点分子库 药物功能重定位化合物库 膜蛋白靶向化合物库 抗癌药物库 抑制剂库 ReFRAME 相关化合物库 NO PAINS 化合物库 内质网应激化合物库 抗代谢疾病化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

(±)-Ibipinabant 362519-49-1 GPCR/G Protein Cannabinoid Receptor SLV 319 Inhibitor BMS6462 (±)-BMS6462 SLV-319 BMS 6462 (±) Ibipinabant BMS-6462 Ibipinabant SLV319 inhibit (±)Ibipinabant (±)-SLV319 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼